Erratum: Innate transcriptional effects by adjuvants on the magnitude, quality, and durability of HIV envelope responses in NHPs (Blood Advances (2017) 1:25 (2329-2342) DOI: 10.1182/bloodadvances.2017011411)


Journal Article

© 2018 by The American Society of Hematology. On page 2339, under "Authorship," the contribution paragraph should have read, "J.R.F., D.E.Z., G.A., and R.A.S. conceived the study and wrote the paper; E.S., N.M.V., P.M., E.D.G., S.W.B., P.S., M.S., S.J., A.S., and D.T.O. developed the vaccine formulations; J.R.F., C.L., N.L.Y., B.G., B.J.F., M. Ackerman, M. Alam, G.F., and G.D.T. designed and carried out experiments; C.J. and D.E.Z. performed the transcriptional analyses; M.J. performed half-life modeling; and A.A., D.E.Z., G.A., and R.A.S. gave conceptual advice and project oversight." The conflict-of-interest paragraph under "Authorship" should have read, "E.S., N.M.V., P.M., E.D.G., S.W.B., P.S., M.S., S.J., and D.T.O. were employees of Novartis Vaccines at this study's conception. A.S. is the chief executive officer and chief science officer of and owns stock in Oncovir, Inc, the company that makes pIC:LC (Hiltonol). The remaining authors declare no competing financial interests." The errors have been corrected in the published article.

Full Text

Duke Authors

Cited Authors

  • Francica, JR; Zak, DE; Linde, C; Siena, E; Johnson, C; Juraska, M; Yates, NL; Gunn, B; De Gregorio, E; Flynn, BJ; Valiante, NM; Malyala, P; Barnett, SW; Sarkar, P; Singh, M; Jain, S; Ackerman, M; Alam, M; Ferrari, G; Salazar, A; Tomaras, GD; O'Hagan, DT; Aderem, A; Alter, G; Seder, RA

Published Date

  • March 13, 2018

Published In

Volume / Issue

  • 2 / 5

Start / End Page

  • 516 -

Electronic International Standard Serial Number (EISSN)

  • 2473-9537

International Standard Serial Number (ISSN)

  • 2473-9529

Digital Object Identifier (DOI)

  • 10.1182/bloodadvances.2018017491

Citation Source

  • Scopus